Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib monotherapy after platinum failure in ERBB-deregulated metastatic urothelial carcinoma
2015-005427-10Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of afatinib in transitional cell carcinoma (TCC) and bladder cancer, sponsored by Boehringer Ingelheim. Primary endpoint: Progression-free survival at 6 months (Cohort A). Started Mar 2016; status: completed.
02
Drugs
afatinib
03
Conditions
transitional cell carcinoma (TCC)bladder cancer
Beyond the preview
Go deeper on 2015-005427-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005427-10.